Abstract
Glioblastomas is the most common malignant primary brain tumors and the prognosis is very poor. With the development of tumor molecular biology, molecular targeted therapy for glioblastomas has become an integral part of its comprehensive treatment. Targeted therapy drugs of glioblastomas are emerging, including tyrosine kinase inhibitors, histone deacetylase inhibitors, phosphatidylinositol 3-kinase inhibitors, hypoxia inducible factor-1α inhibitors, sodium-potassium pump inhibitors, et al. With the development of new molecular targeted therapy, more effective or even treatment measures of glioblastomas might be found, which can provide a new approach for the individualized treatment of glioblastomas. Key words: Glioma; Targeted therapy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
